Keith Kerr
Overview
Explore the profile of Keith Kerr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
6525
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reck M, Syrigos K, Miliauskas S, Vant Westeinde S, Massuti B, Buchner H, et al.
Transl Lung Cancer Res
. 2025 Jan;
13(12):3364-3381.
PMID: 39830745
Background: Anti-angiogenic agents, such as nintedanib and ramucirumab, when combined with docetaxel, are subsequent treatment options in patients with non-small cell lung cancer (NSCLC) who have failed on first-line chemotherapy...
2.
Awad M, Forde P, Girard N, Spicer J, Wang C, Lu S, et al.
J Clin Oncol
. 2025 Jan;
JCO2402239.
PMID: 39778121
Purpose: Neoadjuvant immune checkpoint blockade with nivolumab plus ipilimumab improves overall survival (OS) in non-small cell lung cancer (NSCLC); however, randomized data for resectable lung cancer are limited. We report...
3.
Otto E, Kaspar A, Kerr K, Droemer G, Waddle A
Crit Care Nurse
. 2024 Nov;
44(6):31-34.
PMID: 39615538
Introduction: Noninvasive ventilation therapy is a common approach in acute respiratory failure as an alternative to invasive mechanical ventilation. Assistive communication strategies are necessary to overcome communication impairments and anxiety...
4.
Dacic S, Travis W, Redman M, Saqi A, Cooper W, Borczuk A, et al.
J Thorac Oncol
. 2023 Sep;
18(10):1290-1302.
PMID: 37702631
Introduction: Pathologic response has been proposed as an early clinical trial end point of survival after neoadjuvant treatment in clinical trials of NSCLC. The International Association for the Study of...
5.
Forde P, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad M, et al.
Future Oncol
. 2023 Feb;
19(8):549-557.
PMID: 36815433
What Is This Summary About?: In this article, we summarize results from the ongoing phase 3 CheckMate 816 clinical study that were published in in 2022. The goal of CheckMate...
6.
Forde P, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad M, et al.
N Engl J Med
. 2022 Apr;
386(21):1973-1985.
PMID: 35403841
Background: Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non-small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have shown promising clinical activity; however,...
7.
Horgan D, Curigliano G, Riess O, Hofman P, Buttner R, Conte P, et al.
J Pers Med
. 2022 Jan;
12(1).
PMID: 35055387
Next-generation sequencing (NGS) may enable more focused and highly personalized cancer treatment, with the National Comprehensive Cancer Network and European Society for Medical Oncology guidelines now recommending NGS for daily...
8.
9.
Gadgeel S, Hirsch F, Kerr K, Barlesi F, Park K, Rittmeyer A, et al.
Clin Lung Cancer
. 2021 Jul;
23(1):21-33.
PMID: 34226144
Background: This phase III OAK trial (NCT02008227) subgroup analysis (data cutoff, January 9, 2019) evaluated the predictive value of 2 PD-L1 IHC tests (VENTANA SP142 and Dako 22C3) for benefit...
10.
Horgan D, Ciliberto G, Conte P, Baldwin D, Seijo L, Montuenga L, et al.
Biomed Hub
. 2021 Feb;
5(3):182-223.
PMID: 33564664
Rapid and continuing advances in biomarker testing are not being matched by take-up in health systems, and this is hampering both patient care and innovation. It also risks costing health...